Bruckner-Tuderman L - Search Results

1

Treatment of keratinocytes with 4-phenylbutyrate in epidermolysis bullosa: Lessons for therapies in keratin disorders.

Spörrer M, Prochnicki A, Tölle RC, Nyström A, Esser PR, Homberg M, Athanasiou I, Zingkou E, Schilling A, Gerum R, Thievessen I, Winter L, Bruckner-Tuderman L, Fabry B, Magin TM, Dengjel J, Schröder R, Kiritsi D. Spörrer M, et al. EBioMedicine. 2019 Jun;44:502-515. doi: 10.1016/j.ebiom.2019.04.062. Epub 2019 May 9. EBioMedicine. 2019. PMID: 31078522 Free PMC article.

2

Laminin 332 in junctional epidermolysis bullosa.

Kiritsi D, Has C, Bruckner-Tuderman L. Kiritsi D, et al. Cell Adh Migr. 2013 Jan-Feb;7(1):135-41. doi: 10.4161/cam.22418. Epub 2012 Oct 17. Cell Adh Migr. 2013. PMID: 23076207 Free PMC article. Review.

3

Cell- and protein-based therapy approaches for epidermolysis bullosa.

Nyström A, Bruckner-Tuderman L, Kern JS. Nyström A, et al. Methods Mol Biol. 2013;961:425-40. doi: 10.1007/978-1-62703-227-8_29. Methods Mol Biol. 2013. PMID: 23325662

4

Impaired lymphoid extracellular matrix impedes antibacterial immunity in epidermolysis bullosa.

Nyström A, Bornert O, Kühl T, Gretzmeier C, Thriene K, Dengjel J, Pfister-Wartha A, Kiritsi D, Bruckner-Tuderman L. Nyström A, et al. Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E705-E714. doi: 10.1073/pnas.1709111115. Epub 2018 Jan 5. Proc Natl Acad Sci U S A. 2018. PMID: 29305555 Free PMC article.

5

Injury- and inflammation-driven skin fibrosis: The paradigm of epidermolysis bullosa.

Nyström A, Bruckner-Tuderman L. Nyström A, et al. Matrix Biol. 2018 Aug;68-69:547-560. doi: 10.1016/j.matbio.2018.01.016. Epub 2018 Jan 31. Matrix Biol. 2018. PMID: 29391280 Review.

6

Cytokines as genetic modifiers in K5-/- mice and in human epidermolysis bullosa simplex.

Roth W, Reuter U, Wohlenberg C, Bruckner-Tuderman L, Magin TM. Roth W, et al. Hum Mutat. 2009 May;30(5):832-41. doi: 10.1002/humu.20981. Hum Mutat. 2009. PMID: 19267394

7

Kindlin-1 and -2 have overlapping functions in epithelial cells implications for phenotype modification.

He Y, Esser P, Heinemann A, Bruckner-Tuderman L, Has C. He Y, et al. Am J Pathol. 2011 Mar;178(3):975-82. doi: 10.1016/j.ajpath.2010.11.053. Am J Pathol. 2011. PMID: 21356350 Free PMC article.

8

Molecular mechanisms of phenotypic variability in junctional epidermolysis bullosa.

Kiritsi D, Kern JS, Schumann H, Kohlhase J, Has C, Bruckner-Tuderman L. Kiritsi D, et al. J Med Genet. 2011 Jul;48(7):450-7. doi: 10.1136/jmg.2010.086751. Epub 2011 Feb 28. J Med Genet. 2011. PMID: 21357940 Free article.

9

Rat model for dominant dystrophic epidermolysis bullosa: glycine substitution reduces collagen VII stability and shows gene-dosage effect.

Nyström A, Buttgereit J, Bader M, Shmidt T, Ozcelik C, Hausser I, Bruckner-Tuderman L, Kern JS. Nyström A, et al. PLoS One. 2013 May 23;8(5):e64243. doi: 10.1371/journal.pone.0064243. Print 2013. PLoS One. 2013. PMID: 23717576 Free PMC article.

10

Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms.

Nyström A, Thriene K, Mittapalli V, Kern JS, Kiritsi D, Dengjel J, Bruckner-Tuderman L. Nyström A, et al. EMBO Mol Med. 2015 Sep;7(9):1211-28. doi: 10.15252/emmm.201505061. EMBO Mol Med. 2015. PMID: 26194911 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

394 results

Search Page

Filters